OsteoBiologics Inc.
This article was originally published in Start Up
Executive Summary
Until recently, there were no treatments to replace damaged cartilage. OsteoBiologics Inc., spun out of technology licensed from the University of Texas Health Science Center, has developed a resorbable biopolymer that may stand alone to mechanically replace damaged cartilage, or may serve as a biologically friendly scaffolding for cell therapies and techniques involving growth factors.You may also be interested in...
Biomaterials: Mechanical Engineering Meets Biology
Start-ups developing man-made surrogates for living processes hope to achieve the alchemy of turning base materials into human tissue.
Sarepta Scores Another Remarkable Approval With Vyondys 53 For Duchenne
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Real-World Evidence Fails Another Test At US FDA
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Medtech Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: